• Je něco špatně v tomto záznamu ?

Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review

N. Miura, B. Pradere, K. Mori, H. Mostafaei, F. Quhal, V. Misrai, D. D'Andrea, S. Albisinni, R. Papalia, T. Saika, RM. Scarpa, SF. Shariat, F. Esperto

. 2020 ; 72 (5) : 531-542. [pub] 20200616

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012097

INTRODUCTION: The aim of this review was to summarize the available evidence on the role of metastasis-directed therapy (MDT) and/or prostate-targeted therapy (PTT) in the setting of oligometastatic prostate cancer (PCa). EVIDENCE ACQUISITION: We searched PubMed, the Web of Science, and the Cochrane Library databases. The following keywords were used: ("prostate cancer" OR "prostate carcinoma" OR "prostate neoplasm" OR "prostate tumor") AND ("oligometastatic" OR "oligometastasis" OR "PSMA") AND ("surgery" OR "prostatectomy" OR "radical prostatectomy" OR "cytoreductive" OR "local treatment" OR "radiotherapy" OR "stereotactic" OR "stereotaxic") AND ("survival" OR "mortality"). EVIDENCE SYNTHESIS: After evaluating the selection criteria, 81 studies were evaluated for our endpoints. We included 22 studies for PTT of synchronous mPCa. There have been no randomized studies on cytoreductive prostatectomy (cRP). Four prospective studies showed that cRP was feasible but did not contribute to a positive effect on overall survival (OS). Regarding PTT-radiotherapy, two randomized controlled phase 3 trials showed that OS was improved in men with a low metastatic burden. Regarding MDT of metachronous lymph node recurrence, we included 29 retrospective studies. For MDT of oligometastases, we included 30 studies. One randomized phase 2 trial showed that androgen deprivation therapy-free survival improved with stereotactic body radiation therapy compared to that with surveillance; however, benefits on OS remain unclear. CONCLUSIONS: We performed a comprehensive overview of the current literature on MDT and PTT. The feasibility of MDT and PTT is supported by several retrospective studies. Nevertheless, there remains a lack of high-quality trials to prove its survival benefits. Results from ongoing prospective trials data are awaited.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012097
003      
CZ-PrNML
005      
20210714133300.0
007      
ta
008      
210420s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.23736/S0393-2249.20.03779-0 $2 doi
035    __
$a (PubMed)32550632
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Miura, Noriyoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria - norimiurajp@yahoo.co.jp ; Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan - norimiurajp@yahoo.co.jp
245    10
$a Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review / $c N. Miura, B. Pradere, K. Mori, H. Mostafaei, F. Quhal, V. Misrai, D. D'Andrea, S. Albisinni, R. Papalia, T. Saika, RM. Scarpa, SF. Shariat, F. Esperto
520    9_
$a INTRODUCTION: The aim of this review was to summarize the available evidence on the role of metastasis-directed therapy (MDT) and/or prostate-targeted therapy (PTT) in the setting of oligometastatic prostate cancer (PCa). EVIDENCE ACQUISITION: We searched PubMed, the Web of Science, and the Cochrane Library databases. The following keywords were used: ("prostate cancer" OR "prostate carcinoma" OR "prostate neoplasm" OR "prostate tumor") AND ("oligometastatic" OR "oligometastasis" OR "PSMA") AND ("surgery" OR "prostatectomy" OR "radical prostatectomy" OR "cytoreductive" OR "local treatment" OR "radiotherapy" OR "stereotactic" OR "stereotaxic") AND ("survival" OR "mortality"). EVIDENCE SYNTHESIS: After evaluating the selection criteria, 81 studies were evaluated for our endpoints. We included 22 studies for PTT of synchronous mPCa. There have been no randomized studies on cytoreductive prostatectomy (cRP). Four prospective studies showed that cRP was feasible but did not contribute to a positive effect on overall survival (OS). Regarding PTT-radiotherapy, two randomized controlled phase 3 trials showed that OS was improved in men with a low metastatic burden. Regarding MDT of metachronous lymph node recurrence, we included 29 retrospective studies. For MDT of oligometastases, we included 30 studies. One randomized phase 2 trial showed that androgen deprivation therapy-free survival improved with stereotactic body radiation therapy compared to that with surveillance; however, benefits on OS remain unclear. CONCLUSIONS: We performed a comprehensive overview of the current literature on MDT and PTT. The feasibility of MDT and PTT is supported by several retrospective studies. Nevertheless, there remains a lack of high-quality trials to prove its survival benefits. Results from ongoing prospective trials data are awaited.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a metastázy nádorů $x farmakoterapie $7 D009362
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a nádory prostaty $x farmakoterapie $x patologie $x chirurgie $7 D011471
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, University Hospital of Tours, Tours, France ; EAU Young Urologist Office (YOU), Arnhem, the Netherlands
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Misrai, Vincent $u Department of Urology, Clinique Pasteur, Toulouse, France
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Albisinni, Simone $u Department of Urology, Erasme Hospital, University Clinics of Brussels, University of Brussels, Brussels, Belgium
700    1_
$a Papalia, Rocco $u Department of Urology, Campus Bio-Medico University, Rome, Italy
700    1_
$a Saika, Takashi $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Scarpa, Roberto M $u Department of Urology, Campus Bio-Medico University, Rome, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, University of Jordan, Amman, Jordan $u European Association of Urology Research Foundation, Arnhem, the Netherlands
700    1_
$a Esperto, Francesco $u EAU Young Urologist Office (YOU), Arnhem, the Netherlands $u Department of Urology, Campus Bio-Medico University, Rome, Italy $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u European Society of Residents in Urology (ESRU), Arnhem, the Netherlands
773    0_
$w MED00003372 $t Minerva urologica e nefrologica The Italian journal of urology and nephrology $x 1827-1758 $g Roč. 72, č. 5 (2020), s. 531-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32550632 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714133259 $b ABA008
999    __
$a ok $b bmc $g 1650474 $s 1132476
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 72 $c 5 $d 531-542 $e 20200616 $i 1827-1758 $m Minerva urologica e nefrologica $n Minerva Urol Nefrol $x MED00003372
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace